ImageneBio, Inc. Stock-Based Compensation
ImageneBio, Inc. (IMA) reported Stock-Based Compensation of $1.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- ImageneBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $911.00K.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $876.00K, a 1436.84% increase year-over-year.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $51.00K.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $15.28M.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $15.39M.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $7.63M, a 1.42% increase from fiscal 2022.
- ImageneBio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $7.53M, a 45.35% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $911.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.79M 10-Q · filed 2026-08-05 | $1.84M derived: sum of 3 quarters · filed 2026-08-05 | $17.12M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $876.00K 10-Q · filed 2026-05-07 | $927.00K derived: sum of 2 quarters · filed 2026-05-07 | $16.21M derived: sum of 3 quarters · filed 2026-05-07 | $16.21M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $15.33M derived: sum of 2 quarters · filed 2026-03-10 | $15.33M derived: sum of 3 quarters · filed 2026-08-05 | $15.39M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $15.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.28M derived: sum of 2 quarters · filed 2026-08-05 | $15.34M 10-Q · filed 2025-11-12 | $15.34M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $57.00K 10-Q · filed 2026-08-05 | $1.36M 10-Q · filed 2025-07-24 | $57.00K derived: sum of 3 quarters · filed 2026-08-05 | -$3.22M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $57.00K 10-Q · filed 2026-05-07 | $904.00K 10-Q · filed 2025-05-08 | $57.00K derived: sum of 2 quarters · filed 2026-05-07 | -$3.22M derived: sum of 3 quarters · filed 2026-05-07 | -$1.94M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$3.28M derived: sum of 2 quarters · filed 2026-03-10 | -$2.00M derived: sum of 3 quarters · filed 2026-03-10 | $0.00 10-K · filed 2026-03-10 | $5.29M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.00M derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $4.30M 10-Q · filed 2024-11-07 | $1.75M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | $3.28M 10-Q · filed 2025-07-24 | $5.04M derived: sum of 3 quarters · filed 2025-07-24 | $7.03M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-08 | $3.76M derived: sum of 2 quarters · filed 2025-05-08 | $5.75M derived: sum of 3 quarters · filed 2025-05-08 | $7.63M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.75M derived: sum of 2 quarters · filed 2025-03-06 | $5.63M derived: sum of 3 quarters · filed 2025-03-06 | $7.63M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.88M derived: sum of 2 quarters · filed 2024-11-07 | $5.88M 10-Q · filed 2024-11-07 | $7.74M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.88M 10-Q · filed 2024-08-08 | $5.74M derived: sum of 3 quarters · filed 2024-08-08 | $7.55M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-13 | $3.86M derived: sum of 2 quarters · filed 2024-05-13 | $5.67M derived: sum of 3 quarters · filed 2024-05-13 | $7.63M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $3.67M derived: sum of 2 quarters · filed 2024-03-12 | $5.63M derived: sum of 3 quarters · filed 2024-03-12 | $7.53M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.77M derived: sum of 2 quarters · filed 2023-11-09 | $5.67M 10-Q · filed 2023-11-09 | $7.25M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.85M 10-Q · filed 2023-08-10 | $5.44M derived: sum of 3 quarters · filed 2023-08-10 | $6.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-15 | $3.48M derived: sum of 2 quarters · filed 2023-05-15 | $4.93M derived: sum of 3 quarters · filed 2023-05-15 | $6.19M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.03M derived: sum of 2 quarters · filed 2023-03-14 | $4.29M derived: sum of 3 quarters · filed 2023-03-14 | $5.18M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.71M derived: sum of 2 quarters · filed 2022-11-07 | $3.60M 10-Q · filed 2022-11-07 | $4.25M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.15M 10-Q · filed 2022-08-11 | $2.80M derived: sum of 3 quarters · filed 2022-08-11 | $3.21M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $885.00K 10-Q · filed 2022-05-12 | $1.53M derived: sum of 2 quarters · filed 2022-05-12 | $1.95M derived: sum of 3 quarters · filed 2022-05-12 | $2.31M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.07M derived: sum of 2 quarters · filed 2022-03-17 | $1.42M derived: sum of 3 quarters · filed 2022-03-17 | $1.80M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $418.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $772.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.15M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $729.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $375.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |